These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23296546)

  • 1. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
    Yomo S; Hayashi M; Cho N
    J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
    Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    J Neurosurg; 2020 Feb; 132(2):503-511. PubMed ID: 30738402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
    Kim JM; Miller JA; Kotecha R; Chao ST; Ahluwalia MS; Peereboom DM; Mohammadi AM; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Abraham J; Moore H; Budd GT; Suh JH
    Neuro Oncol; 2019 May; 21(5):659-668. PubMed ID: 30726965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
    Yomo S; Oda K
    Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
    Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
    Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older.
    Yomo S; Hayashi M
    BMC Cancer; 2016 Dec; 16(1):948. PubMed ID: 27978813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery.
    Tam M; Narayana A; Raza S; Kunnakkat S; Golfinos JG; Parker EC; Novik Y
    Med Oncol; 2014 Feb; 31(2):832. PubMed ID: 24390418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Treatment Options for Breast Cancer Brain Metastases.
    Raghunath A; Desai K; Ahluwalia MS
    Curr Treat Options Oncol; 2019 Feb; 20(3):19. PubMed ID: 30771009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases.
    Grandhi R; Kondziolka D; Panczykowski D; Monaco EA; Kano H; Niranjan A; Flickinger JC; Lunsford LD
    J Neurosurg; 2012 Aug; 117(2):237-45. PubMed ID: 22631694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article.
    Kondziolka D; Kano H; Harrison GL; Yang HC; Liew DN; Niranjan A; Brufsky AM; Flickinger JC; Lunsford LD
    J Neurosurg; 2011 Mar; 114(3):792-800. PubMed ID: 20887087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
    Hammerman A; Greenberg-Dotan S; Feldhamer I; Bitterman H; Yerushalmi R
    PLoS One; 2015; 10(9):e0138229. PubMed ID: 26375590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience.
    Gao C; Wang F; Suki D; Strom E; Li J; Sawaya R; Hsu L; Raghavendra A; Tripathy D; Ibrahim NK
    Int J Cancer; 2021 Feb; 148(4):961-970. PubMed ID: 32748402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer.
    Gori S; Puglisi F; Moroso S; Fabi A; La Verde N; Frassoldati A; Tarenzi E; Garrone O; Vici P; Laudadio L; Cretella E; Turazza M; Foglietta J; Leonardi V; Cavanna L; Barni S; Galanti D; Russo A; Marchetti F; Valerio M; Lunardi G; Alongi F; Inno A
    Clin Breast Cancer; 2019 Aug; 19(4):e501-e510. PubMed ID: 31204290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.